Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05013554 | Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors | terminated | Phase 1 | 44 | SanofiINDUSTRY | 6 | Sep 15, 2025 | clinicaltrials |
| NCT04478266 | Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer(AMEERA-5) | terminated | Phase 3 | 1,068 | SanofiINDUSTRY | 30 | Sep 11, 2025 | clinicaltrials |
| NCT07166367 | Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer | terminated | Phase 2 | 3 | National Cancer Centre, SingaporeOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03838367 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC | terminated | Phase 1 / Phase 2 | 10 | CytoDyn, Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04815083 | Fluorescence Imaging of Carcinoma During Breast Conserving Surgery | terminated | Phase 3 | 57 | SBI ALApharma Canada, Inc.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT03501979 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | terminated | Phase 2 | 17 | University of Alabama at BirminghamOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01703754 | Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. | terminated | Phase 2 | 12 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT02423902 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | terminated | Phase 1 / Phase 2 | 9 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT02807597 | Real-time Intraoperative Breast Cancer Visualization for Margin Assessment | terminated | Phase 1 / Phase 2 | 9 | Samuel AchilefuOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05560685 | SMART-ER: Symptom Monitoring With Patient-reported Outcomes(SMART-ER) | terminated | N/A | 10 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05623488 | CAR T Cells in Mesothelin-Expressing Breast Cancer | terminated | Phase 1 | 2 | University of PennsylvaniaOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT05435352 | Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment(PEAR-TNBC) | terminated | — | 34 | Ourotech, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | terminated | Phase 2 | 49 | Washington University School of MedicineOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04227327 | Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)(HERMIONE-7) | terminated | Phase 2 | 31 | University of Milano BicoccaOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04042051 | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer(Panthera) | terminated | Phase 1 | 2 | Cancer Trials IrelandNETWORK | 2 | Jul 22, 2025 | clinicaltrials |
| NCT05300958 | Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT04752332 | A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer(eMonarcHER) | terminated | Phase 3 | 111 | Eli Lilly and CompanyINDUSTRY | 20 | Jul 15, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT01722890 | CharactHer. ICORG 12-09, V3 | terminated | — | 130 | Cancer Trials IrelandNETWORK | 2 | Jul 8, 2025 | clinicaltrials |
| NCT01726322 | Ovarian Reserve in Premenopausal Breast Cancer | terminated | — | 216 | Cancer Trials IrelandNETWORK | 1 | Jul 8, 2025 | clinicaltrials |
| NCT03816839 | Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)(AMEERA-2) | terminated | Phase 1 | 10 | SanofiINDUSTRY | 1 | Jul 7, 2025 | clinicaltrials |
| NCT05511844 | Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | terminated | Phase 1 | 25 | Orum Therapeutics USA, Inc.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | terminated | Phase 1 | 57 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | terminated | — | 10 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05031065 | Prognostic Indicators for Radiation-induced Breast Fibrosis | terminated | — | 4 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03248492 | A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) | terminated | Phase 2 | 253 | Daiichi SankyoINDUSTRY | 9 | Jun 26, 2025 | clinicaltrials |
| NCT01231932 | Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors | terminated | — | 163 | National Institute of Nursing Research (NINR)NIH | 1 | Jun 19, 2025 | clinicaltrials |
| NCT05447910 | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer | terminated | — | 21 | Mayo ClinicOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05041101 | Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | terminated | Phase 1 / Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05243641 | Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | terminated | Phase 1 / Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer(neoBREASTIM) | terminated | Phase 1 / Phase 2 | 2 | Institut CurieOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04251169 | Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression(TATEN) | terminated | Phase 2 | 20 | SOLTI Breast Cancer Research GroupOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer(PERSEVERE) | terminated | Phase 2 | 52 | Bryan Schneider, MDOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT05744557 | Vapocoolant Analgesia for Breast Lymphoscintigraphy | terminated | N/A | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03742349 | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | terminated | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 9 | May 18, 2025 | clinicaltrials |
| NCT04252859 | [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma | terminated | Phase 2 | 44 | University of UtahOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT00195091 | Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer | terminated | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06231693 | Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil | terminated | — | 2 | AstraZenecaINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT03596073 | Topical Calcipotriene Treatment for Breast Cancer Immunoprevention | terminated | Phase 1 | 43 | Massachusetts General HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT05067972 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors(C4431001) | terminated | Phase 1 | 30 | PfizerINDUSTRY | 2 | May 6, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 15, 2025source: clinicaltrials